InspireMD, Inc. (NSPR) is a publicly traded Healthcare sector company. As of May 21, 2026, NSPR trades at $1.00 with a market cap of $49.18M and a P/E ratio of -1.33. NSPR moved +1.00% today. Year to date, NSPR is -48.19%; over the trailing twelve months it is -54.34%. Its 52-week range spans $0.97 to $3.80. Analyst consensus is strong buy with an average price target of $3.67. Rallies surfaces NSPR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
InspireMD Q1 Revenue Soars 122% to $3.4M, EPS Beats Estimates: InspireMD posted Q1 EPS of -$0.16, beating estimates of -$0.19 and improving from -$0.22 a year ago. Revenue rose 122% year-over-year to $3.4 million, exceeding projections by over 25%, while the company holds a negative P/E of -2.07 and awaits new FDA trial approvals expected later in 2026.
| Metric | Value |
|---|---|
| Price | $1.00 |
| Market Cap | $49.18M |
| P/E Ratio | -1.33 |
| EPS | $-0.76 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.80 |
| 52-Week Low | $0.97 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $8.98M |
| Net Income | $-48.79M |
| Gross Margin | 29.50% |
3 analysts cover NSPR: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $3.67.